Detalles de la búsqueda
1.
Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
Cancer Immunol Immunother;
72(7): 2197-2204, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36856834
2.
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Cancer Immunol Immunother;
72(9): 2949-2960, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37247023
3.
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Cancer Immunol Immunother;
72(11): 3717-3726, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37787790
4.
MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development.
Hepatol Res;
47(1): 80-94, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27138942
5.
Dr.VIS v2.0: an updated database of human disease-related viral integration sites in the era of high-throughput deep sequencing.
Nucleic Acids Res;
43(Database issue): D887-92, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25355513
6.
Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer.
Int Immunopharmacol;
129: 111642, 2024 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325044
7.
Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
Int J Radiat Oncol Biol Phys;
118(5): 1461-1471, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37433375
8.
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study.
Int J Surg;
2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38704621
9.
Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
Front Immunol;
14: 1109292, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36742297
10.
Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.
Front Immunol;
14: 1084843, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36733485
11.
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
World J Gastroenterol;
29(10): 1614-1626, 2023 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36970591
12.
The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.
Am J Cancer Res;
13(8): 3582-3590, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37693157
13.
A novel cuproptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma.
Heliyon;
8(11): e11768, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36468143
14.
Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma.
Am J Transl Res;
11(3): 1428-1445, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30972172
15.
Identification of the molecular relationship between intravenous leiomyomatosis and uterine myoma using RNA sequencing.
Sci Rep;
9(1): 1442, 2019 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30723247
16.
The fusion landscape of hepatocellular carcinoma.
Mol Oncol;
13(5): 1214-1225, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30903738
17.
Editorial: Advances in immunotherapy and combination therapy for biliary tract cancers.
Front Oncol;
13: 1360649, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38260831
18.
Comparison of harmonic scalpel and conventional technique in the surgery for breast cancer: A systematic review and meta-analysis.
Indian J Cancer;
55(4): 348-358, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30829269
19.
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration.
Transl Lung Cancer Res;
11(10): 2164-2166, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36386458
20.
Gallbladder papillary neoplasms share pathological features with intraductal papillary neoplasm of the bile duct.
Oncotarget;
8(19): 31532-31539, 2017 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28415560